Anti-F. tularensis LVS Lipopolysaccharide (LPS) [12] Antibody

This mouse IgG2a monoclonal antibody [12] was generated against sublethal infection with F. tularensis LVS and is reactive against both F. tularensis LVS and F. tularensis SchuS4 protein Lipopolysaccharide (LPS).

Highlights:

  • Reacts with F. tularensis LVS and F. tularensis SchuS4 LPS
  • Does not react with F. novicida
  • Suitable for Western Blot, Immunoprecipitation, ELISA and Immunofluorescence applications

Francisella tularensis is a small pathogenic gram-negative, nonmotile, aerobic bacteria and the causative agent of tularemia. Also known as "rabbit fever" the highly contagious bacteria can be spread from animals to humans, through a vector such as fleas or mosquitoes. F. tularensis has been considered to be encapsulated for over 40 years based on the rough colony phenotype and presence of polysachharides structures on the organism. Francisella tularensis is classified as a Category A biological agent and symptoms include fever, headache and body aches.

From the laboratory of Anne G. Savitt, PhD, Stony Brook University

The Investigator's Annexe Part of The Investigator's Annexe program.

Catalog Number Product Size AVAILABILITY Price Qty
ESB005
Anti-F. tularensis LVS Lipopolysaccharide (LPS) [12] Antibody
100ug In stock
Regular Price:$321.00
Specifications

Product Type: Antibody
Antigen: Lipopolysaccharide (LPS)
Isotype: IgG2a
Clonality: Monoclonal
Clone Name: 12
Reactivity: Francisella tularensisLVS and SchuS4. Does not react with but not F. novicida
Immunogen: Sublethal infection with F. tularensisLVS
Species Immunized: Mouse
Purification Method: FPLC on Protein G Sepharose
Method Used to Determine Concentration: OD280 (Nanodrop)
Buffer: PBS
Tested Applications: WB, IP, ELISA, IF. Use at 1-10 ug/mL
Concentration: 2 mg/mL
Storage: -20C
Shipped: Cold packs

Provider
From the laboratory of Anne G. Savitt, PhD, Stony Brook University
References
  1. Savitt AG, Mena-Taboada P, Monsalve G, Benach JL. Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy. Clin Vaccine Immunol. 2009 Mar;16(3):414-22.

If you publish research with this product, please let us know so we can cite your paper.

Loading...